-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Staging
-
Expert Commentary on the Clinical and Surgical Implications of VPI in NSCLC
Dr. Ramón Rami-Porta offers a surgical perspective on the secondary analysis of the CALGB 140503 trial and discusses what, if any, influence the data will have on staging guidelines.
-
Challenging the Smoking Status Quo: Making the Case for Non-Anatomical Factors to Refine Lung Cancer Staging
Using the IASLC 9th Edition Staging Database, Dr. Lawson Eng and colleagues evaluated the association between smoking status at diagnosis and OS.
-
New Nodal Descriptor Classification Potentially Better at Differentiating Patients
The IASLC’s proposed new classification of N descriptor is potentially better at differentiating patients with lung cancer into different stages, according to the results of a study presented during the mini oral session, “MA09: Prognosis and Staging,” held on Sunday. According to a presentation by Dariusz Dziedzic, MD, National Research Institute of Chest Diseases, Warsaw, Poland,…